title: Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
abstract: OBJECTIVE
  This randomized, noncomparative, parallel-group study was designed to evaluate the pathologic complete response (pCR) rate of combined doxorubicin plus paclitaxel (AP) and doxorubicin plus cyclophosphamide (AC) as neoadjuvant chemotherapy in patients with previously untreated breast cancer who were unsuitable for conservative surgery.
  
  
  METHODS
  A total of 200 patients with T2-3, N0-1, M0 disease were randomly assigned in a 2:1 ratio to receive preoperative chemotherapy with either doxorubicin 60 mg/m(2) plus paclitaxel 200 mg/m(2) as a 3-hour infusion (AP) or doxorubicin 60 mg/m(2) plus cyclophosphamide 600 mg/m(2) (AC) every 3 weeks for 4 courses followed by surgery.
  
  
  RESULTS
  A pCR (eradication of invasive carcinoma in tumor and in axillary lymph nodes) was found in 16% and 10% of patients in the AP and AC arms, respectively, by study center pathologists, and in 8% and 6% of patients, respectively, by independent pathologists. Patients with pCRs tended to have unifocal disease, tumors with negative hormonal receptor status, and less differentiation (Scarff, Bloom, and Richardson scale grade 3). Breast-conserving surgery was performed in 58% and 45% of patients in the AP and AC arms, respectively. An objective clinical response was achieved in 89% of patients in the AP arm and 70% in the AC arm. At a median follow-up of 31 months, disease-free survival (DFS) was higher in patients who reached pCR versus those without pCR (91% v 70%).
  
  
  CONCLUSIONS
  The encouraging pathologic and clinical responses of patients with breast cancer after neoadjuvant chemotherapy with doxorubicin plus paclitaxel warrant additional investigation of paclitaxel in the neoadjuvant setting of breast cancer management.
authors.affiliation: Institut Curie, Department of Medical Oncology, 26 rue d'Ulm, 75005 Paris, France. veronique.dieras@curie.net
authors.forename: Véronique
authors.initials: V
authors.lastname: Diéras
authors.forename: Pierre
authors.initials: P
authors.lastname: Fumoleau
authors.forename: Gilles
authors.initials: G
authors.lastname: Romieu
authors.forename: Michèle
authors.initials: M
authors.lastname: Tubiana-Hulin
authors.forename: Moïse
authors.initials: M
authors.lastname: Namer
authors.forename: Louis
authors.initials: L
authors.lastname: Mauriac
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Guastalla
authors.forename: Eric
authors.initials: E
authors.lastname: Pujade-Lauraine
authors.forename: Pierre
authors.initials: P
authors.lastname: Kerbrat
authors.forename: Philippe
authors.initials: P
authors.lastname: Maillart
authors.forename: Frédérique
authors.initials: F
authors.lastname: Pénault-Llorca
authors.forename: Marc
authors.initials: M
authors.lastname: Buyse
authors.forename: Pierre
authors.initials: P
authors.lastname: Pouillart
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel